Cryptic phosphoribosylase activity of NAMPT restricts the virion incorporation of viral proteins
View on PubMed → | DOI | Publisher
Plain-language summary
Published 2024 in Nat Metab, this work by Feng S and collaborators tackles a specific question within science-focused NMN/NAD+ research.
Key findings reported by the authors
- Preclinical animal study in Nat Metab (2024) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
What this means for Malaysian buyers
For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.